Are Analysts Expecting A Better 2020 For Amicus Therapeutics Inc (FOLD)?

Amicus Therapeutics Inc (FOLD) concluded trading on Wednesday at a closing price of $11.37, with 3.87 million shares of worth about $43.96 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 3.08% during that period and on April 3, 2024 the price remained unchanged. Currently the company’s common shares owned by public are about 293.59M shares, out of which, 286.50M shares are available for trading.

Stock saw a price change of -0.52% in past 5 days and over the past one month there was a price change of -15.53%. Year-to-date (YTD), FOLD shares are showing a performance of -19.87% which increased to 2.52% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.70 but also hit the highest price of $14.57 during that period. The average intraday trading volume for Amicus Therapeutics Inc shares is 3.08 million. The stock is currently trading -4.32% below its 20-day simple moving average (SMA20), while that difference is down -9.86% for SMA50 and it goes to -7.93% lower than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Amicus Therapeutics Inc (NASDAQ: FOLD) currently have 293.59M outstanding shares and institutions hold larger chunk of about 106.62% of that.

The stock has a current market capitalization of $3.36B and its 3Y-monthly beta is at 0.76. It has posted earnings per share of -$0.52 in the same period. It has Quick Ratio of 2.52 while making debt-to-equity ratio of 2.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FOLD, volatility over the week remained 3.06% while standing at 3.60% over the month.

Analysts are in expectations that Amicus Therapeutics Inc (FOLD) stock would likely to be making an EPS of -$0.06 in the current quarter, while forecast for next quarter EPS is -$0.02 and it is $0.4 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.08 which is -$0.03 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.18 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 100.97% while it is estimated to increase by 7948.83% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on December 19, 2023 offering an Overweight rating for the stock and assigned a target price range of between $15 and $20 to it. Coverage by Morgan Stanley stated Amicus Therapeutics Inc (FOLD) stock as an Equal-weight in their note to investors on September 09, 2022, suggesting a price target of $14 for the stock. On April 13, 2022, Goldman Resumed their recommendations, while on January 14, 2022, SVB Leerink Upgrade their ratings for the stock with a price target of $16. Stock get a Buy rating from Stifel on November 15, 2021.

Most Popular

Related Posts